Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals

Journal of Alzheimer's Disease

Volumn 23, Issue 2, 2011, Pages 239-248

  Squitti, Rosanna ^a,b   Ghidoni, Roberta ^a   Scrascia, Federica ^b   Benussi, Luisa ^a   Panetta, Valentina ^a   Pasqualetti, Patrizio ^a,c   Moffa, Filomena ^a   Bernardini, Silvia ^a   Ventriglia, Mariacarla ^a,b   Binetti, Giuliano ^a   Rossini, Paolo Maria ^a,c  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c Epidemiology and Biostatistics   (Italy)

Author keywords

Alzheimer's disease; apolipoprotein E; copper; mild cognitive impairment

Indexed keywords

APOLIPOPROTEIN E4; CERULOPLASMIN; COPPER; IRON; TRANSFERRIN;

ALZHEIMER DISEASE; ANALYTICAL PARAMETERS; ARTICLE; CARDIOVASCULAR RISK; CERULOPLASMIN BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; COPPER BLOOD LEVEL; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FEMALE; GERIATRIC PATIENT; HUMAN; HYPOTHESIS; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; TOTAL ANTIOXIDANT CAPACITY; TRANSFERRIN BLOOD LEVEL;

EID: 79951563119     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101098     Document Type: Article

References (69)

1. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 1985-1992. (Pubitemid 33143977)
2. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, Kokmen E, Waring SC, Kurland LT (1995) Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 273, 1274-1278.
3. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P,Winblad B (2006) Mild cognitive impairment. Lancet 367, 1262-1270.
4. Visser PJ, Verhey FR, Scheltens P, Cruts M, Ponds RW, Van Broeckhoven CL, Jolles J (2002) Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. J Neurol 249, 312-319. (Pubitemid 34212275)
5. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 94, 9866-9868. (Pubitemid 27408156)
6. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52. (Pubitemid 28277534)
7. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, SmithMA(2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21, 3017-3023. (Pubitemid 32323483)
8. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H,Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767. (Pubitemid 32678256)
9. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ (2004) Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61, 59-66. (Pubitemid 38067415)
10. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001) Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1133-1142.
11. Bush AI, Tanzi RE (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5, 421-432. (Pubitemid 351952485)
12. Squitti R, Lupoi D, Pasqualetti P, Dal Forno G, Vernieri F, Chiovenda P, Rossi L, Cortesi M, Cassetta E, Rossini PM (2002) Elevation of serum copper levels in Alzheimer's disease. Neurology 59, 1153-1161. (Pubitemid 35192384)
13. Arnal N, Cristalli DO, de Alaniz MJ, Marra CA (2010) Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res 1319, 118-130.
14. Gonzalez C, Martin T, Cacho J, BrenasMT, Arroyo T, Garcia- Berrocal B, Navajo JA, Gonzalez-Buitrago JM (1999) Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 29, 637-642. (Pubitemid 29322377)
15. Smorgon C, Mari E, Atti AR, Dalla Nora E, Zamboni PF, Calzoni F, Passaro A, Fellin R (2004) Trace elements and cognitive impairment: An elderly cohort study. Arch Gerontol Geriatr Suppl 9, 393-402. (Pubitemid 38822890)
16. Agarwal R, Kushwaha SS, Tripathi CB, Singh N, Chhillar N (2008) Serum copper in Alzheimer's disease and vascular dementia. Indian J Clin Biochem 23, 369-374.
17. Bocca B, Forte G, Petrucci F, Pino A, Marchione F, Bomboi G, Senofonte O, Giubilei F, Alimonti A (2005) Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. Ann Ist Super Sanita 41, 197-203. (Pubitemid 43169864)
18. Sevym S UO,Tamer I,Doǧu O, OzgeA(2007) Can serum levels of copper and zinc distinguish Alzheimer's patients from normal subjects? J Neurol Sci (Turkish) 24, 197-205. (Pubitemid 47521082)
19. Gerhardsson L, Lundh T, Minthon L, Londos E (2008) Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 25, 508-515. (Pubitemid 351957413)
20. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, CunyG(1989) Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 35, 275-282. (Pubitemid 20015238)
21. Kapaki E, Segditsa J, Zournas C, Xenos D, Papageorgiou C (1989) Determination of cerebrospinal fluid and serum lead levels in patients with amyotrophic lateral sclerosis and other neurological diseases. Experientia 45, 1108-1110. (Pubitemid 20007925)
22. Mattiello G, Gerotto M, Favarato M, Lazzri F, Gasparoni G, Gomirato L, Mazzolini G, Scarpa G, Zanaboni V, Pilone MG, Zatta PF (1993) Plasma microelement analysis from Alzheimer's and multi-infartual dementia patients. In Alzheimer's Diseases: Advances in Clinical and Basic Research, Corain B, Iqbal K, Nicolini M, Winbland B, Wisniewski HM, Zatta PF, eds., John Wiley & Sons, Chichester, pp. 267-272.
23. Molina JA, Jimenez-Jimenez FJ, Aguilar MV, Meseguer I, Mateos-Vega CJ, Gonzalez-Munoz MJ, de Bustos F, Porta J, Orti-Pareja M, Zurdo M, Barrios E, Martinez-ParaMC(1998) Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm 105, 479-488. (Pubitemid 28365030)
24. Ozcankaya R, Delibas N (2002) Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: Crosssectional study. Croat Med J 43, 28-32. (Pubitemid 34157862)
25. Sedighi B, Shafa MA, Shariati M (2006) A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman, Iran. Neurology Asia 11, 107-109.
26. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir, Baldvinsson M, Johannesson T (1998) Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. a case-control study. Dement Geriatr Cogn Disord 9, 239-242. (Pubitemid 28377223)
27. Vural H, Demirin H, Kara Y, Eren I, Delibas N (2010) Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol 24, 169-173.
28. Kessler H, Pajonk FG, Meisser P, Schneider-Axmann T, Hoffmann KH, Supprian T, HerrmannW, Obeid R, Multhaup G, Falkai P, Bayer TA (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. J Neural Transm 113, 1763-1769. (Pubitemid 44657672)
29. Pajonk FG, Kessler H, Supprian T, Hamzei P, Bach D, Schweickhardt J, Herrmann W, Obeid R, Simons A, Falkai P, Multhaup G, Bayer TA (2005) Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J Alzheimers Dis 8, 23-27. (Pubitemid 41267320)
30. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308.
31. RitchieCW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691. (Pubitemid 37521621)
32. Squitti R, Salustri C (2009) Agents complexing copper as a therapeutic strategy for the treatment of Alzheimer's disease. Curr Alzheimer Res 6, 476-487.
33. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, doubleblind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
34. Brewer GJ (2010) Copper toxicity in the general population. Clin Neurophysiol 121, 459-460.
35. Squitti R, Barbati G, Rossi L, Ventriglia M, Dal Forno G, Cesaretti S, Moffa F, Caridi I, Cassetta E, Pasqualetti P, Calabrese L, Lupoi D, Rossini PM (2006) Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 67, 76-82. (Pubitemid 44305465)
36. Squitti R, Bressi F, Pasqualetti P, Bonomini C, Ghidoni R, Binetti G, Cassetta E, Moffa F, Ventriglia M, Vernieri F, Rossini PM (2009) Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology 72, 50-55.
37. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R (2010) Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am J Alzheimers Dis Other Dement 25, 490-497.
38. Hoogenraad TU (2007) Measuring Hypercupremia in Blood of Patients with Alzheimer's Disease is Logical, but the Utility of Measuring Free-copper has to be Proven, Tijdschrift voor, Utrechts.
39. Altahus JS, Quinn JF, Kaye JA, Newsome DA, Bisgaier CL, Kanzer SH (2008) Free copper measured directly in serum using a novel device is elevated in Alzheimer's disease. Invest Ophthalmol Vis Sci 49, 5218.
40. Salustri C, Barbati G, Ghidoni R, Quintiliani L, Ciappina S, Binetti G, Squitti R (2010) Is cognitive function linked to serum free copper levels? A cohort study in a normal population. Clin Neurophysiol 121, 502-507.
41. Albert M, Smith LA, Scherr PA, Taylor JO, Evans DA, Funkenstein HH (1991) Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci 57, 167-178.
42. Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, Vellas B, Touchon J (2006) Mild cognitive impairment (MCI) in medical practice: A critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's disease. J Neurol Neurosurg Psychiatry 77, 714-718. (Pubitemid 43837193)
43. Rossini PM, Buscema M, Capriotti M, Grossi E, Rodriguez G, Del Percio C, Babiloni C (2008) Is it possible to automatically distinguish resting EEG data of normal elderly versus mild cognitive impairment subjects with high degree of accuracy? Clin Neurophysiol 119, 1534-1545.
44. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34, 939-944. (Pubitemid 14076461)
45. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
46. Squitti R, Pasqualetti P, Dal Forno G, Moffa F, Cassetta E, Lupoi D, Vernieri F, Rossi L, Baldassini M, Rossini PM (2005) Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64, 1040-1046. (Pubitemid 40388458)
47. Abe A, Yamashita S, Noma A (1989) Sensitive, direct colorimetric assay for copper in serum. Clin Chem 35, 552-554. (Pubitemid 19111064)
48. Beckett JM, HartleyTF, BallMJ(2009) Evaluation of the Randox colorimetric serum copper and zinc assays against atomic absorption spectroscopy. Ann Clin Biochem 46, 322-326.
49. Schosinsky KH, Lehmann HP, Beeler MF (1974) Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 20, 1556-1563.
50. Walshe JM (2003)Wilson's disease: The importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 40, 115-121. (Pubitemid 36359861)
51. Squitti R, Ventriglia M, Barbati G, Cassetta E, Ferreri F, Dal Forno G, Ramires S, Zappasodi F, Rossini PM (2007) 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm 114, 1589-1594. (Pubitemid 350212005)
52. Morris MC, Evans DA, Tangney CC, Bienias JL, Schneider JA,Wilson RS, Scherr PA(2006) Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 63, 1085-1088. (Pubitemid 44232313)
53. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24, 915-919. (Pubitemid 36962976)
54. Selhub J, Jacques PF, Bostom AG, Wilson PW, Rosenberg IH (2000) Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification. Public Health Rev 28, 117-145. (Pubitemid 32487824)
55. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, StreitW, Strohmeyer R, Tooyoma I, van Muiswinkel FL,Veerhuis R,Walker D,Webster S,Wegrzyniak B,Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421. (Pubitemid 30349107)
56. LinderMC(2001) Copper and genomic stability in mammals. Mutat Res 475, 141-152. (Pubitemid 32280808)
57. Treiber C, Simons A, Strauss M, Hafner M, Cappai R, Bayer TA, Multhaup G (2004) Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem 279, 51958-51964. (Pubitemid 39656565)
58. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX (2002) Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 277, 44670-44676. (Pubitemid 36159056)
59. Bush AI, Masters CL, Tanzi RE (2003) Copper, beta-amyloid, and Alzheimer's disease:Tapping a sensitive connection. Proc Natl Acad Sci U S A 100, 11193-11194. (Pubitemid 37205909)
60. White AR, Reyes R, Mercer JF, Camakaris J, Zheng H, Bush AI, Multhaup G, Beyreuther K, Masters CL, Cappai R (1999) Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 842, 439-444. (Pubitemid 29475178)
61. Bush AI (2003) The metallobiology of Alzheimer's disease. Trends Neurosci 26, 207-214. (Pubitemid 36412003)
62. Scheinberg IH, Sternlieb I (1965)Wilson's disease. Annu Rev Med 16, 119-134.
63. Squitti R, Quattrocchi CC, Salustri C, Rossini PM (2008) Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease. Prion 2, 23-27.
64. Smith QR (2000) Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 130, 1016S-1022S. (Pubitemid 30173636)
65. Hartter DE, BarneaA(1988) Brain tissue accumulates 67copper by two ligand-dependent saturable processes. A high affinity, lowcapacity and a lowaffinity, high capacity process. J Biol Chem 263, 799-805. (Pubitemid 18044707)
66. Chutkow JG (1978) Evidence for uptake of nonceruloplasminic copper in the brain: Effect of ionic copper and amino acids. Proc Soc Exp Biol Med 158, 113-116. (Pubitemid 8375724)
67. Stuerenburg HJ (2000) CSF copper concentrations, bloodbrain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease. J Neural Transm 107, 321-329. (Pubitemid 30162693)
68. Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (1999) Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 53, 1488-1494. (Pubitemid 29491942)
69. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234. (Pubitemid 43238346)